[go: up one dir, main page]

CU24480B1 - Anticuerpos anti-transtiretina - Google Patents

Anticuerpos anti-transtiretina

Info

Publication number
CU24480B1
CU24480B1 CU2017000097A CU20170097A CU24480B1 CU 24480 B1 CU24480 B1 CU 24480B1 CU 2017000097 A CU2017000097 A CU 2017000097A CU 20170097 A CU20170097 A CU 20170097A CU 24480 B1 CU24480 B1 CU 24480B1
Authority
CU
Cuba
Prior art keywords
ttr
antibodies
transtiretin
accumulation
amyloidosis
Prior art date
Application number
CU2017000097A
Other languages
English (en)
Other versions
CU20170097A7 (es
Inventor
Avijit Chakrabartty
Jeffrey N Higaki
Yue Liu
Tarlochan S Nijjar
Original Assignee
Prothena Biosciences Ltd
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd, Univ Health Network filed Critical Prothena Biosciences Ltd
Publication of CU20170097A7 publication Critical patent/CU20170097A7/es
Publication of CU24480B1 publication Critical patent/CU24480B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<p>La invención proporciona anticuerpos que se unen específicamente la transtiretina (TTR). Los anticuerpos pueden usarse para tratar o efectuar la profilaxis de enfermedades o trastornos asociados con acumulación de TTR o acumulación de depósitos de TTR (por ejemplo, amiloidosis TTR). Los anticuerpos también pueden usarse para diagnosticar la amiloidosis TTR e inhibir o reducir la agregación de TTR, entre otras aplicaciones.<br /> </p>
CU2017000097A 2015-01-28 2016-01-28 Anticuerpos anti-transtiretina CU24480B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562109002P 2015-01-28 2015-01-28
US201562266556P 2015-12-11 2015-12-11
PCT/IB2016/050415 WO2016120810A1 (en) 2015-01-28 2016-01-28 Anti-transthyretin antibodies

Publications (2)

Publication Number Publication Date
CU20170097A7 CU20170097A7 (es) 2018-03-13
CU24480B1 true CU24480B1 (es) 2020-03-04

Family

ID=55299694

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2017000097A CU24480B1 (es) 2015-01-28 2016-01-28 Anticuerpos anti-transtiretina

Country Status (32)

Country Link
US (1) US20160251418A1 (es)
EP (2) EP3250592B1 (es)
JP (2) JP6748086B2 (es)
KR (2) KR102598180B1 (es)
CN (1) CN107406499B (es)
AU (1) AU2016210888C1 (es)
CA (1) CA2974912A1 (es)
CL (2) CL2017001924A1 (es)
CO (1) CO2017008476A2 (es)
CU (1) CU24480B1 (es)
DK (1) DK3250592T3 (es)
EA (1) EA036080B1 (es)
ES (1) ES2934656T3 (es)
FI (1) FI3250592T3 (es)
HR (1) HRP20221538T1 (es)
HU (1) HUE060878T2 (es)
IL (1) IL253633B (es)
LT (1) LT3250592T (es)
MX (1) MX2017009806A (es)
NZ (1) NZ733896A (es)
PE (1) PE20180217A1 (es)
PH (1) PH12017501318A1 (es)
PL (1) PL3250592T3 (es)
PT (1) PT3250592T (es)
RS (1) RS63906B1 (es)
SA (1) SA517382002B1 (es)
SG (2) SG11201706124VA (es)
SI (1) SI3250592T1 (es)
TW (2) TWI786505B (es)
UA (1) UA122142C2 (es)
WO (1) WO2016120810A1 (es)
ZA (1) ZA201705663B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018007922A2 (en) * 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
BR112020006791A2 (pt) * 2017-10-06 2020-12-01 Prothena Biosciences Limited métodos de detecção de transtirretina
US11267877B2 (en) 2017-10-06 2022-03-08 Prothena Biosciences Limited Anti-transthyretin antibodies
CA3083356A1 (en) * 2017-11-29 2019-06-06 Prothena Biosciences Limited Lyophilized formulation of a monoclonal antibody against transthyretin
DK3876713T3 (da) 2018-11-09 2024-10-28 Neurimmune Ag Patientafledt amyloidxenotransplantatgnavermodel
KR20220156040A (ko) 2020-03-18 2022-11-24 에이엘-에스 파마 아게 미스폴드 sod1 어세이
IL298135A (en) 2020-05-12 2023-01-01 Neurimmune Ag Combination therapy for ttr amyloidosis
WO2021231982A1 (en) * 2020-05-14 2021-11-18 City Of Hope Smc1a antibodies and uses thereof
JP2023548005A (ja) * 2020-10-28 2023-11-15 ノヴォ ノルディスク アー／エス 抗トランスサイレチン抗体およびその使用方法
CN113845593B (zh) * 2021-10-27 2023-03-10 福州迈新生物技术开发有限公司 抗α-SMA蛋白单克隆抗体、细胞系及其应用
CA3239708A1 (en) 2021-12-03 2023-06-08 Aubin MICHALON Novel potency assay for antibody-based drugs and useful means therefor
US20240228637A9 (en) * 2022-10-19 2024-07-11 Ibio, Inc. Chemokine receptor 8 (ccr8) antibodies
WO2024105062A1 (en) 2022-11-15 2024-05-23 Neurimmune Ag Methods for treating or preventing transthyretin-mediated amyloidosis
TW202440636A (zh) * 2023-03-21 2024-10-16 美商傳記５５有限公司 Ｃｄ１９／ｃｄ３８多特異性抗體
WO2024240562A1 (en) 2023-05-19 2024-11-28 Neurimmune Ag Novel immunotherapy for musculoskeletal disorders and conditions

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
NZ513144A (en) 1999-02-05 2003-05-30 Samsung Electronics Co Ltd Image texture retrieving method and apparatus thereof
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
EP2298809A3 (en) 2001-07-12 2012-02-15 FOOTE, Jefferson Super humanized antibodies
ES2289174T3 (es) 2001-12-28 2008-02-01 Amgen Fremont Inc. Anticuerpos contra el antigeno muc-18.
MXPA05005481A (es) 2002-11-29 2005-07-25 Boehringer Ingelheim Pharma Nuevos genes de la fosfotransferasa de neomicina y procedimiento para la seleccion de celulas recombinantes de produccion elevada.
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
DE602005014805D1 (de) 2004-11-10 2009-07-16 Boehringer Ingelheim Pharma Verwendung von durchflusszytometrischer analyse zur optimierung von zellbankingstrategien für cho-zellen
US8703096B2 (en) 2006-04-21 2014-04-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Beta-amyloid PET imaging agents
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
WO2008070593A2 (en) 2006-12-01 2008-06-12 Seattle Genetics, Inc. Variant target binding agents and uses thereof
MX2009009156A (es) 2007-03-02 2009-09-04 Boehringer Ingelheim Pharma Mejora de la produccion de proteina.
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
FI20115165A0 (fi) * 2011-02-21 2011-02-21 Polysackaridforskning I Uppsala Ab Terapeuttisia ja diagnostisia menetelmiä
US9534048B2 (en) * 2012-08-24 2017-01-03 University Health Network Antibodies to TTR and methods of use
JP2016514091A (ja) * 2013-02-08 2016-05-19 ミスフォールディング ダイアグノスティクス， インコーポレイテッド トランスサイレチン抗体およびその使用
EP3022225B1 (en) * 2013-07-19 2021-09-29 Board Of Regents Of the University Of Texas System Transthyretin amyloid-selective and polyreactive catabodies
BR112020006791A2 (pt) 2017-10-06 2020-12-01 Prothena Biosciences Limited métodos de detecção de transtirretina

Also Published As

Publication number Publication date
AU2016210888A1 (en) 2017-08-10
UA122142C2 (uk) 2020-09-25
JP2020185009A (ja) 2020-11-19
CL2017001924A1 (es) 2018-04-27
IL253633B (en) 2021-06-30
CN107406499B (zh) 2021-10-22
CL2022003027A1 (es) 2023-06-09
SA517382002B1 (ar) 2021-11-25
EA036080B1 (ru) 2020-09-23
AU2016210888B2 (en) 2021-11-04
HRP20221538T1 (hr) 2023-03-03
RS63906B1 (sr) 2023-02-28
NZ733896A (en) 2024-11-29
SG11201706124VA (en) 2017-08-30
AU2016210888C1 (en) 2022-06-02
PL3250592T3 (pl) 2023-06-19
HUE060878T2 (hu) 2023-04-28
EA201791712A1 (ru) 2017-12-29
JP7028923B2 (ja) 2022-03-02
PH12017501318B1 (en) 2018-02-05
CU20170097A7 (es) 2018-03-13
DK3250592T3 (en) 2023-01-09
FI3250592T3 (fi) 2023-01-13
TWI718122B (zh) 2021-02-11
KR20230156164A (ko) 2023-11-13
LT3250592T (lt) 2023-02-10
EP3250592B1 (en) 2022-10-05
PT3250592T (pt) 2022-12-28
KR20170106469A (ko) 2017-09-20
TW202124436A (zh) 2021-07-01
US20160251418A1 (en) 2016-09-01
CA2974912A1 (en) 2016-08-04
IL253633A0 (en) 2017-09-28
ZA201705663B (en) 2018-08-29
TW201632554A (zh) 2016-09-16
SG10202101763VA (en) 2021-04-29
BR112017016330A2 (pt) 2018-04-03
CN107406499A (zh) 2017-11-28
EP4134379A1 (en) 2023-02-15
TWI786505B (zh) 2022-12-11
JP2018506277A (ja) 2018-03-08
MX2017009806A (es) 2018-08-15
PE20180217A1 (es) 2018-01-31
ES2934656T3 (es) 2023-02-23
JP6748086B2 (ja) 2020-09-02
SI3250592T1 (sl) 2023-03-31
KR102598180B1 (ko) 2023-11-03
PH12017501318A1 (en) 2018-02-05
EP3250592A1 (en) 2017-12-06
WO2016120810A1 (en) 2016-08-04
KR102677203B1 (ko) 2024-06-20
CO2017008476A2 (es) 2018-01-16

Similar Documents

Publication Publication Date Title
CO2017008476A2 (es) Anticuerpos anti-transtiretina
CO2017008482A2 (es) Anticuerpos anti-transtiretina
CU20170096A7 (es) Anticuerpos anti-transtiretina
CU20200021A7 (es) Anticuerpos anti-transtiretina
CL2017002401A1 (es) Anticuerpos contra icos
CU20170052A7 (es) Moléculas de anticuerpo que se unen a pd-l1
ECSP19044183A (es) (aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas
CU24481B1 (es) Moléculas de anticuerpo que se unen a lag-3
CU24427B1 (es) Moléculas de anticuerpo que se unen a tim-3
MX2018006385A (es) Moleculas de anticuerpo contra april y usos de las mismas.
CR20170095A (es) Anticuerpos anti-cll-1 e inmunoconjugados referencias recíprocas con solicitudes relacionadas
WO2018007924A3 (en) Anti-transthyretin antibodies
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
WO2018007923A3 (en) Anti-transthyretin antibodies
AR113345A1 (es) Anticuerpos anti-transtiretina
AR103549A1 (es) Anticuerpos anti-transtiretina
EA202090891A1 (ru) Молекулы антител против cd138 и их применение
EA202090898A1 (ru) Антитранстиретиновые антитела
AR103548A1 (es) Anticuerpos anti-transtiretina